<DOC>
	<DOCNO>NCT00648050</DOCNO>
	<brief_summary>The objective study investigate bioequivalence Mylan 's verapamil HCl extended-release 300 mg capsule Schwarz 's Verelan® PM extended-release 300 mg capsule follow even administration single , oral 300 mg ( 1 x 300 mg ) dose administration fasting condition .</brief_summary>
	<brief_title>Fasting Study Verapamil HCl Extended-Release Capsules 300 mg Verelan® PM Extended-Release Capsules 300 mg</brief_title>
	<detailed_description />
	<mesh_term>Verapamil</mesh_term>
	<criteria>1 . Age : 18 year old . 2 . Sex : Male and/or nonpregnant , nonlactating female . 1 . Women childbearing potential must negative serum ( β HCG ) pregnancy test perform within 21 day prior start study even prior dose administration . If dose schedule Sunday Monday , serum β HCG testing may collect within 48 hour prior dose study period . An additional serum ( β HCG ) pregnancy test perform upon completion study . 2 . Women childbearing potential must practice abstinence use acceptable form contraception throughout duration study . No hormonal contraceptive hormonal replacement therapy permit study . Acceptable form contraception include follow : 1. intrauterine device place least 3 month prior start study remain place study period , 2. barrier method contain use conjunction spermicidal agent , 3. surgical sterilization 3 . Women consider childbearing potential one follow report documented medical history : 1. postmenopausal absence menses least one ( 1 ) year , 2. bilateral oophorectomy without hysterectomy absence bleed least 6 month , 3. total hysterectomy 4 . During course study , study screen study exit include washout period , men woman childbearing potential must use spermicide contain barrier method contraception addition current contraceptive method . This advice document informed consent form . 3 . Weight : At least 60 kg ( 132 lb ) men 48 kg ( 106 lb ) woman subject Body Mass Index ( BMI ) great equal 19 less equal 30 ( see Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS ) . 4 . All subject judge normal healthy prestudy medical evaluation ( physical examination , laboratory evaluation , hepatitis B hepatitis C test , HIV test , 12lead ECG , urine drug screen include amphetamine , barbiturate , benzodiazepine , cannabinoid , cocaine , opiate screen , phencyclidine , methadone ) perform within 21 day initial dose study medication . 1 . Institutionalized subject use . 2 . Social Habits : 1 . Use tobacco product within 1 year start study . 2 . Ingestion alcoholic , caffeine xanthinecontaining food beverage within 48 hour prior initial dose study medication . 3 . Ingestion vitamins herbal product within 7 day prior initial dose study medication . 4 . Any recent , significant change dietary exercise habit . 5 . A positive test drug include urine drug screen . 6 . History drug and/or alcohol abuse . 3 . Medications : 1 . Use prescription overthecounter ( OTC ) medication within 14 day prior initial dose study medication . 2 . Use hormonal contraceptive hormone replacement therapy within 3 month prior study medication dosing . 3 . Use medication know alter hepatic enzyme activity within 28 day prior initial dose study medication . 4 . Diseases : 1 . History significant hepatic , renal , pulmonary , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic disease . 2 . History significant cardiovascular disease , include history know accessory bypass tract ( WolffParkinsonWhite LownGanongLevine ) , paroxysmal supraventricular tachycardia , atrial flutter , hypotension . 3 . Acute illness time either prestudy medical evaluation dosing . 4 . A positive HIV , hepatitis B , hepatitis C test . 5 . Abnormal clinically significant laboratory test result : 1 . Clinically significant deviation Guide Clinically Relevant Abnormalities ( See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS ) . 2 . Abnormal clinically relevant ECG tracing . 6 . Donation loss significant volume blood plasma ( &gt; 450 mL ) within 28 day prior initial dose study medication . 7 . Subjects receive investigational drug within 30 day prior initial dose study medication . 8 . Allergy hypersensitivity verapamil hydrochloride related product . 9 . History difficulty swallow , gastrointestinal disease could affect drug absorption . 10 . Bradycardia le 50 beats/minute supine position , measure ECG , screen visit prior Period I Day 1 dosing . 11 . Sitting pulse rate le 60 beat per minute sit systolic blood pressure le 90 great 140 sit diastolic blood pressure le 60 great 90 fiveminute rest period Screening Visit prior Period I Day 1 dosing . 12 . Subjects whose diurnal sleep pattern may alter ( i.e. , shift worker ) . 13 . Consumption grapefruit grapefruit containing product within 7 day drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>